PET-derived radiomics and artificial intelligence in breast cancer: a systematic review
L Urso, L Manco, A Castello, L Evangelista… - International Journal of …, 2022 - mdpi.com
Breast cancer (BC) is a heterogeneous malignancy that still represents the second cause of
cancer-related death among women worldwide. Due to the heterogeneity of BC, the correct …
cancer-related death among women worldwide. Due to the heterogeneity of BC, the correct …
Fibroblast-activated protein inhibitor PET/CT: cancer diagnosis and management
S Kuyumcu, Y Sanli, RM Subramaniam - Frontiers in oncology, 2021 - frontiersin.org
Fibroblast activation protein (FAP), overexpressed on cancer-associated fibroblasts (CAFs),
is a novel target for molecular imaging of various tumors. Recently, the development of …
is a novel target for molecular imaging of various tumors. Recently, the development of …
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in …
Purpose The goal of this guideline/procedure standard is to assist nuclear medicine
physicians, other nuclear medicine professionals, oncologists or other medical specialists …
physicians, other nuclear medicine professionals, oncologists or other medical specialists …
EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the …
RC Delgado Bolton, N Aide, PM Colletti… - European journal of …, 2021 - Springer
In most patients with ovarian carcinoma, the diagnosis is reached when the disease is long
past the initial stages, presenting already an advanced stage, and they usually have a very …
past the initial stages, presenting already an advanced stage, and they usually have a very …
[HTML][HTML] Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell …
H Hubbeling, EA Silverman, L Michaud… - … and cellular therapy, 2023 - Elsevier
Greater tumor burden before CD19-targeted chimeric antigen receptor T cell (CAR-T)
therapy predicts lower complete response rate and shorter overall survival (OS) in patients …
therapy predicts lower complete response rate and shorter overall survival (OS) in patients …
Reproducibility of [18F] FDG PET/CT liver SUV as reference or normalisation factor
GJC Zwezerijnen, JJ Eertink, MC Ferrández… - European journal of …, 2023 - Springer
Introduction Although visual and quantitative assessments of [18F] FDG PET/CT studies
typically rely on liver uptake value as a reference or normalisation factor, consensus or …
typically rely on liver uptake value as a reference or normalisation factor, consensus or …
Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy
Purpose Chimeric antigen receptor T-cell (CAR T) therapy is capable of eliciting durable
responses in patients with relapsed/refractory (R/R) lymphomas. However, most treated …
responses in patients with relapsed/refractory (R/R) lymphomas. However, most treated …
Electroencephalogram based brain-computer interface: Applications, challenges, and opportunities
Abstract Brain-Computer Interfaces (BCI) is an exciting and emerging research area for
researchers and scientists. It is a suitable combination of software and hardware to operate …
researchers and scientists. It is a suitable combination of software and hardware to operate …
Toward high-throughput artificial intelligence-based segmentation in oncological PET imaging
An array of artificial intelligence (AI) techniques in the field of medical imaging has emerged
in the past decade for automated image segmentation. 1 Medical image segmentation seeks …
in the past decade for automated image segmentation. 1 Medical image segmentation seeks …
Tumor burden measured by 18F-FDG PET/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma
R Hong, E Tan Su Yin, L Wang, X Zhao, L Zhou… - Frontiers in …, 2021 - frontiersin.org
Chimeric antigen receptor (CAR) T-cell therapy has exhibited promising clinical outcomes in
treating relapsed/refractory (R/R) B-cell hematologic malignancies. Current studies have …
treating relapsed/refractory (R/R) B-cell hematologic malignancies. Current studies have …